Company News from Basel-Stadt

From now on, our new section „Company News from Basel-Stadt“ will regularly feature and showcase a selection of corporate success stories from companies in Basel-Stadt.

Grand opening of first new building in Baloise Park

In mid-September 2020, following five years of construction work, the international insurance provider Baloise has officially inaugurated its new group headquarters in Basel-Stadt. It is the first of a total of three new buildings that together with the existing Baloise tower will constitute the Baloise Park.

In addition to Baloise Park, the Helvetia Campus in Basel also has plans for creating new and attractive living and working environments that are sure to further strengthen the standing of Basel as a leading insurance and business location.

Weitere Informationen:

Baloise Park öffnet seine Türen

Baloise Park, Website


News from Technologiepark Basel

The Technologiepark Basel is the premier address for early-stage tech start-ups in Basel, run by the Economic Development unit of the canton of Basel-Stadt. We proudly  present to you a selection of recent success stories of our tenants

  • Versameb

a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer to advance its lead molecule into clinical development.

Versameb, News

  • NBE-Therapeutics

California’s Exelixis has partnered with Swiss firm NBE-Therapeutics to discover and develop several antibody-drug conjugates (ADCs) in oncology.

NBE Therapeutics in the News

  • BioVersys

BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of anti-microbial resistance (AMR) candidates against infectious diseases into first in human clinical trials. The company has also strengthened its board with the appointment of Dr. Eduard Holdener.

BioVersys, News

  • Polyneuron

Polyneuron announces a CHF 14 million extension of its Series A round, bringing the total funding to CHF 36.5 million.

Polyneuron, News

  • Monte Rosa Therapeutics

Monte Rosa Therapeutics announces $96 Million Series B Financing to advance its small molecule-based protein degradation platform.

Monte Rosa Therapeutics, Newsroom


We are thrilled to announce that the start-up from the canton of Basel-Stadt has been ranked among the top "50 Swiss start-ups in which to invest in 2020." was the only company from the digital health sector in the investment ranking by the leading Swiss economic magazine Bilan. Congratulations! Ranked Among the Top 50 Startups in Which To Invest in 2020!